Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Medicine Research Profiles
Home
Profiles
Departments, Divisions and Centers
Research output
Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab
Michelle A. Gill
, Andrew H. Liu
, Agustin Calatroni
, Rebecca Z. Krouse
, Baomei Shao
, Allison Schiltz
, James E. Gern
, Alkis Togias
, William W. Busse
Division of Allergy & Pulmonary Medicine
Institute of Clinical and Translational Sciences (ICTS)
Bursky Center for Human Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Article
›
peer-review
165
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
FcRI
100%
Antiviral Response
100%
IFN Response
100%
Plasmacytoid Dendritic Cells
100%
Omalizumab
100%
Asthma Exacerbation
80%
Omalizumab Treatment
80%
MRNA Expression
60%
Rhinovirus
60%
IgE Cross-linking
60%
Influenza
40%
Quantitative RT-PCR
40%
Risk Factors
20%
Clinical Outcomes
20%
Clinical Observation
20%
Virus
20%
Protein Level
20%
Protein Expression
20%
Pathway Genes
20%
Flow Cytometry
20%
Identify Risk
20%
Supernatant
20%
Children with Asthma
20%
Inner child
20%
Acute Asthma Exacerbation
20%
Increased Vulnerability
20%
Allergic Asthma
20%
Viral Respiratory Infections
20%
Cell Pellet
20%
Atopy
20%
IgE Levels
20%
Allergic Sensitization
20%
Exacerbation Rate
20%
Virus-induced Asthma
20%
IFN Pathway
20%
Immunology and Microbiology
Plasmacytoid Dendritic Cell
100%
Omalizumab
100%
Asthma Exacerbation
66%
Immunoglobulin E
66%
Cross Linking
50%
Rhinovirus
50%
Asthma
33%
Quantitative Reverse Transcription Polymerase Chain Reaction
33%
Influenza
33%
Virus
33%
Atopy
16%
Protein Expression
16%
Supernatant
16%
Allergic Asthma
16%
Sensitization
16%
Infection
16%
Susceptibility
16%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Antivirus Agent
100%
Omalizumab
100%
Immunoglobulin E
66%
Rhinovirus
50%
Messenger RNA
50%
Flow Cytometry
16%
Statistical Modeling
16%
Viral Respiratory Tract Infection
16%
Allergic Asthma
16%
Atopy
16%
Biochemistry, Genetics and Molecular Biology
Plasmacytoid Dendritic Cell
100%
Omalizumab
100%
Immunoglobulin E
66%
Cross-Link
50%
Rhinovirus
50%
Messenger RNA
50%
Quantitative Reverse Transcription Polymerase Chain Reaction
33%
Protein Expression
16%
Supernatant
16%
Sensitization
16%
Flow Cytometry
16%